Somatostatin Receptor Type Market Top Leading Players with Strategies and Forecast 2027

The global somatostatin receptor type market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Somatostatin is a hormone that regulates a wide variety of physiological functions and is produced by numerous tissues in the body mostly in the nervous and digestive systems. Additionally, it inhibits the secretion of other hormones such as the activity of the gastrointestinal tract and the rapid reproduction of normal and tumour cells. The major factor driving the demand for somatostatin receptor type is the increasing prevalence of cancer across the globe.

According to the National Cancer Institute (NCI), it was estimated that 1,806,590 new cases of cancer will be diagnosed in the US with a mortality rate of 606,520 people in 2020. In men, prostate, lung, and colorectal cancers will account for an estimated 43% of all cancers diagnosed while for women, the three most common cancers are breast, lung, and colorectal which will account for an estimated 50% of all new cancer diagnoses in women in 2020. Furthermore, there were 18.1 million new cases and 9.5 million cancer-related mortalities globally in 2018 which is anticipated to rise to 29.5 million and the number of cancer-related mortalities to 16.4 million by 2040. Hence, the increasing prevalence of cancer is driving the demand for somatostatin receptor types as their activation results in inhibition of cell proliferation.

To Request a Sample of our Report on Somatostatin Receptor Type Market: https://www.omrglobal.com/request-sample/somatostatin-receptor-type-market

Some major players in the market include Merck KGaA, and Chiasma, Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in June 2020, Chiasma, Inc. announced the approval of MYCAPSSA (octreotide) capsules by the U.S. Food and Drug Administration (FDA). It is an oral somatostatin analog (SSA) used for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.

Market Coverage

• The market number available for - 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

Segment Covered-

· By Type

· By Application

Regions Covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

Competitive Landscape- Merck KGaA, and Chiasma, Inc., among others.

(Get 15% Discount on Buying this Report)

A full Report of Somatostatin Receptor Type Market is Available @ https://www.omrglobal.com/industry-reports/somatostatin-receptor-type-market

Global Somatostatin Receptor Type Market Report by Segment

By Type

• sstr1

• sstr2A

• sstr2B

• sstr3

• sstr4

• sstr5

By Application

• Alzheimer's Disease

• Cancer

• Hormonal Disorder

• Others

Global Somatostatin Receptor Type Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.